Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on ESSENTRA PLC. We currently have 2 research reports from 1 professional analysts.
|27Feb17 10:55||RNS||Holding(s) in Company|
|27Feb17 10:14||RNS||Holding(s) in Company|
|22Feb17 17:00||RNS||Holding(s) in Company|
|21Feb17 16:34||RNS||Director/PDMR Shareholding|
|20Feb17 17:53||RNS||Holding(s) in Company|
|20Feb17 14:45||RNS||Director/PDMR Shareholding|
|17Feb17 07:08||RNS||Final Results|
Frequency of research reports
Research reports on
Doing it better
21 Feb 17
A new CEO-led corporate recovery programme is underway and many key ingredients to achieve this are visible. Acknowledging lower FY17e earnings, clearer strategic direction and turnaround indicators should be more tangible from H2. We expect positive newsflow to gather momentum.
Taking a long hard look
01 Feb 17
FY16 has been a disappointing one for Essentra, but a new CEO is a catalyst for change. Having clearly identified some key issues, short-term remedial action is to be followed by a full strategic update later in the year. The near-term goal is to deliver more robust operational performance before driving profitable growth thereafter. FY16 results are scheduled for 17 February.
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
Time to go over weight
24 Feb 17
We believe equity investors are taking an unnecessarily cautious stance on the construction sector. Forward looking indicators (e.g. consumer confidence, construction PMIs and housing starts) point to a stable market and recent sales LFL are particularly encouraging (e.g. Marshalls). Near term margins may suffer temporary distortions as inflationary pressures build. However, history has shown that modest input cost inflation is actually a positive for earnings growth in the sector. Therefore, as we move into 2018, margin trends are likely to surprise on the upside.
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals
N+1 Singer - Morning Song 21-02-2017
21 Feb 17
Abzena (ABZA LN) Contract bookings strong; US costs higher than expected | City of London Investment Group (CLIG LN) Earnings and interim dividend in line, some modest growth in FuM | dotdigital Group (DOTD LN) Good H1; broadening avenues of growth | Grafenia (GRA LN) Weak print volumes | Vernalis (VER LN) Interims highlight increasing Tuzistra™ scrip volume